Showing 1 - 20 results of 29 for search '"рефрактерная артериальная гипертензия"', query time: 0.89s Refine Results
  1. 1
    Academic Journal

    Contributors: Работа частично выполнена по Государственному заданию в рамках бюджетной темы №АААА-А17- 117112850280-2

    Source: Rational Pharmacotherapy in Cardiology; Vol 16, No 4 (2020); 557-563 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 4 (2020); 557-563 ; 2225-3653 ; 1819-6446

    File Description: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/2253/2013; Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. DOI:10.1093/eurheartj/ehy339.; Funder J.W., Carey R.M., Mantero F., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-916. DOI:10.1210/jc.2015-4061.; Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab. 2015;100(1):1-10. DOI:10.1210/jc.2014-3663.; Mulatero P, Monticone S, Bertello C, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826-33. DOI:10.1210/jc.2013-2805.; Надеева Р.А., Камалиева Г.Р., Ягфарова Р.Р. Первичный гиперальдостеронизм в структуре артериальной гипертонии: актуальность проблемы. Вестник Современной Клинической Медицины. 2015;8(6):98-102. DOI:10.20969/vskm.2015.8(6).98-102.; Young W.F. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-48. DOI:10.1111/joim.12831.; Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. DOI:10.1016/j.jacc.2005.01.015.; Monticone S., D'Ascenzo F., Moretti C., et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41-50. DOI:10.1016/S2213-8587(17)30319-4.; Prada E.T.A., Burrello J., Reincke M., Williams T.A. Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension. 2017;70:875-81. DOI:10.1161/HYPERTENSIONAHA.117.10111.; Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический Архив. 2018;9:115-22. DOI:10.26442/terarkh2018909115-122.; Omata K., Satoh F., Morimoto R., et al. Cellular and Genetic Causes of Idiopathic Hyperaldosteronism. Hypertension. 2018;72(4):874-80. DOI:10.1161/HYPERTENSIONAHA.118.11086.; Liao C.W., Lin Y.T., Wu X.M., et al.; TAIPAI Study Group. The relation among aldosterone, galectin3, and myocardial fibrosis: a prospective clinical pilot follow-up study. J Investig Med. 2016;64(6):1109-13. DOI:10.1136/jim-2015-000014.; Lee H.H., Hung C.S., Wu X.M., et al.; Taipai Study Group. Myocardial ultrasound tissue characterization of patients with primary aldosteronism. Ultrasound Med Biol. 2013;39(1):54-61. DOI:10.1016/j.ultrasmedbio.2012.08.023.; Grytaas M.A., Sellevåg K., Thordarson H.B., et al. Cardiac magnetic resonance imaging of myocardial mass and fibrosis in primary aldosteronism. Endocr Connect. 2018;7(3):413-24. DOI:10.1530/EC18-0039.; Цыганкова О.В., Калинина Е.М., Латынцева Л.Д., Воевода М.И. Успешный опыт коррекции рефрактерной артериальной гипертонии и морбидного ожирения у пациента с синдромом обструктивного апноэ сна тяжелой степени. Российский Кардиологический Журнал. 2018;(5):74-80. DOI:10.15829/1560-4071-2018-5-74-80.; Dudenbostel T., Calhoun D.A. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens. 2011;26(5):281-7. DOI:10.1038/jhh.2011.4.; Calhoun D.A., Nishizaka M.K., Zaman M.A., Harding S.M. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125(1):112-7. DOI:10.1378/chest.125.1.112.; Gonzaga C.C., Gaddam K.K., Ahmed M.I., et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010;6(4):363-8. DOI:10.1097/01.hjh.0000379812.66839.11.; Di Murro A., Petramala L., Cotesta D., et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism. Journal of the Renin-Angiotensin-Aldosterone System. 2010;11(3):165-72. DOI:10.1177/1470320310366581.; Ахадов Ш.В., Рузбанова Г.Р., Молчанова Г.С. Эволюционные стадии низкорениновой артериальной гипертонии. Рациональная Фармакотерапия в Кардиологии. 2010;6(1):68-72. DOI:10.20996/1819-6446-2010-6-1-68-72.; Hanon O., Boully C., Caillard L., et al. Treatment of hypertensive patients with diabetes and microalbuminuria with combination indapamide SR/amlodipine: retrospective analysis of NESTOR. Am J Hypertens. 2015;28:1064-71. DOI:10.1093/ajh/hpu297.; Маркель А.Л. Генетика и патофизиология низкорениновой артериальной гипертонии. Вавиловский Журнал Генетики и Селекции. 2018;22(8):1000-8. DOI:10.18699/vj18.443.; Мельниченко Г.А., Платонова Н.М., Бельцевич Д.Г. и др. Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма. Consilium Medicum. 2017;19(4):75-85. DOI:10.26442/2075-1753_19.4.75-85.; Williams T.A., Reincke M. Management of endocrine disease: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol. 2018;179(1):R19- R29. DOI:10.1530/EJE-17-0990.; Mulatero P., Stowasser M., Loh K.C., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism. 2004;89(3):1045-50. DOI:10.1210/jc.2003-031337.; Дедов И.И., Мельниченко Г.А., ред. Инциденталома надпочечников (диагностика и дифференциальная диагностика). Клинические рекомендации для врачей первичного звена. М.: ФГБУ ЭНЦ; 2015.; Young W.F., Stanson A.W., Thompson G.B., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227-35. DOI:10.1016/j.surg.2004.06.051.; Nwariaku F.E., Miller B.S., Auchus R., et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006;141(5):497-502. DOI:10.1001/archsurg.141.5.497.; Цыганкова О.В., Худякова А.Д., Латынцева Л.Д., Ложкина Н.Г. Сердечно-сосудистый континуум: от факторов риска до систолической сердечной недостаточности. Атеросклероз. 2017;13(4):42-6. DOI:10.15372/ATER20170407.; https://www.rpcardio.com/jour/article/view/2253

  2. 2
    Academic Journal

    Source: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 64, № 1 (2019); 15-24 ; Российский вестник перинатологии и педиатрии; Том 64, № 1 (2019); 15-24 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2019-64-1

    File Description: application/pdf

    Relation: https://www.ped-perinatology.ru/jour/article/view/815/739; The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2 suppl): 555–576.; Flynn J.T., Kaelber D.C., Baker-Smith C.M., Blowey D., Carroll A.E., Daniels S.R. et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140(3): e20171904. DOI:10.1542/peds.2017-1904; Lurbea E., Agabiti-Roseic E., Cruickshankd J.K., Dominiczake A., Erdinef S., Hirthg A. et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34(10): 1887–1920. DOI:10.1097/HJH.0000000000001039; Диагностика, лечение и профилактика артериальной гипертензии у детей и подростков. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2009; 8(4): приложение1: 1–32.; Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 1–98. DOI:10.1093/eurheartj/ehy339; Nerenberg K.A., Zarnke K.B., Leung A.A., Dasgupta K., Butalia S., McBrien K. Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol 2018; 34(5): 506–525. DOI:10.1016/j.cjca.2018.02.022; Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383: 1899–1911. DOI:10.1016/S0140-6736(14)60685-11; Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014; 32: 2285–2295.; Theodore R.F., Broadbent J., Nagin D., Ambler A., Hogan S., Ramrakha S. et al. Childhood to early-midlife systolic blood pressure trajectories: early-life predictors, effect modifiers, and adult cardiovascular outcomes. Hypertension 2015; 66(6): 1108–1115. DOI:10.1161/HYPERTENSIONAHA.115.05831; Torrance B., McGuire K.A., Lewanczuk R., McGavock J. Overweight, physical activity and high blood pressure in children: a review of the literature. Vasc Health Risk Manag 2007; 3(1): 139–149.; Farpour-Lambert N.J., Aggoun Y., Marchand L.M., Martin X.E., Herrmann F.R., Beghetti M. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54(25): 2396–2406. DOI:10.1016/j.jacc.2009.08.030; Kelley G.A., Kelley K.S., Tran Z.V. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6(1): 8–16.; Tompkins C.L., Moran K., Preedom S., Brock D.W. Physical activity-induced improvements in markers of insulin resistance in overweight and obese children and adolescents. Curr Diabetes Rev 2011; 7(3): 164–170.; Damasceno M.M., de Araújo M.F., deFreitas R.W., de Almeida P.C., Zanetti M.L. The association between blood pressure in adolescents and the consumption of fruits, vegetables and fruit juice – an exploratory study. J Clin Nurs 2011; 20(11–12): 1553–1560. DOI:10.1111/j.1365-2702.2010.03608.x; Moore L.L., Bradlee M.L., Singer M.R., Qureshi M.M., Buendia J.R., Daniels S.R. Dietary approaches to stop hypertension (DASH) eating pattern and risk of elevated blood pressure in adolescent girls. Br J Nutr 2012; 108(9): 1678–1685. DOI:10.1017/S000711451100715X; Saneei P., Hashemipour M., Kelishadi R., Rajaei S., Esmaillzadeh A. Effects of recommendations to follow the dietary approaches to stop hypertension (DASH) diet v. usual dietary advice on childhood metabolic syndrome: a randomized cross-over clinical trial. Br J Nutr 2013; 110(12): 2250–2259. DOI:10.1017/S0007114513001724; Yang Q., Zhang Z, Kuklina E.V., Fang J., Ayala C., Hong Y. et al. Sodium intake and blood pressure among US children and adolescents. Pediatrics 2012; 130(4): 611–619. DOI:10.1542/peds.2011-3870; Resnicow K., McMaster F., Bocian A., Harris D., Zhou Y., Snetselaar L. et al. Motivational interviewing and dietary counseling for obesity in primary care: an RCT. Pediatrics 2015; 135(4): 649–657. DOI:10.1542/peds.2014-1880; Broccoli S., Davoli A.M., Bonvicini L., Fabbri A., Ferrari E., Montagna G. et al. Motivational interviewing to treat overweight children: 24-month follow-up of a randomized controlled trial. Pediatrics 2016; 137(1): e20151979. DOI:10.1542/peds.2015-1979; Chu P.Y., Campbell M.J., Miller S.G., Hill K.D. Anti-hypertensive drugs in children and adolescents. World J Cardiol 2014; 6: 234–244. DOI:10.4330/wjc.v6.i5.234; Dionne J.M., Harris K.C., Benoit G., FeberJ., Poirier L., Cloutier L. et al. Hypertension Canada’s 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. Can J Cardiol 2017; 33(5): 557–688. DOI:10.1016/j.cjca.2017.03.007; Croxtall J.D. Valsartan: in children and adolescents with hypertension. Paediatr Drugs 2012; 14(3): 201–207. DOI:10.2165/11208990-000000000-00000; Wühl E., Trivelli A., Picca S., Litwin M., Peco-Antic A., Zurowska A. et al.; ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 2009; 361(17): 1639–1650. DOI:10.1056/NEJ-Moa0902066; Wells T., Blumer J., Meyers K.E. Valsartan Pediatric Hypertension Study Group. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) 2011; 13(5): 357–365. DOI:10.1111/j.1751-7176.2011.00432; Flynn J.T., Newburger J.W., Daniels S.R., Sanders S.P., Portman R.J., Hogg R.J. et al.; PATH-1 Investigators. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 2004; 145(3): 353–359.; Webb N.J., Shahinfar S., Wells T.G., Massaad R., Gleim G.W., Santoro E.P. et al. Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 2012; 82(7): 819–826. DOI:10.1038/ki.2012.210; Gartenmann A.C., Fossali E., von Vigier R.O., Simonetti G., Schmidtko J., Edefonti A. et al. Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 2003; 64(4): 1450–1454.; Flynn J.T. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20(5):631–635.; Soffer B., Zhang Z., Miller K. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003; 16: 795–800. DOI:10.1016/S0895-7061(03)00900-2; Seeman T., Gilik J., Vondrak K., Simková E., Flögelová H., Hladíková M. et al. Regression of left-ventricular hypertrophyin children and adolescents with hypertension during Ramipril monotherapy. Am J Hypertens 2007; 20: 990–996.; Baker-Smith C.M., Benjamin D.K., Califf R.M. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 2010; 87: 668–671. DOI:10.1038/clpt.2009.231; Shahinfar S., Cano F., Soffer B.A., Ahmed T., Santoro E.P., Zhang Z. et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005; 18 (2, pt 1): 183–190.; Schaefer F., Coppo R., Bagga A., Senguttuvan P., Schlosshauer R., Zhang Y. et al. Efficacy and safety of valsartan in hypertensive children 6 mon to 5 years of age. J Hypertens 2013; 31(5): 993–1000. DOI:10.1097/HJH.0b013e32835f5721; Schaefer F., Litwin M., Zachwieja J., Zurowska A., Turi S., Grosso A. et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 2011; 29(12): 2484–2490. DOI:10.1097/HJH.0b013e32834c625c; Trachtman H., Hainer J.W., Sugg J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10: 743–750. DOI:10.1111/j.1751-7176.2008.00022; Hazan L., Hernández Rodriguez O.A., Bhorat A.E., Miyazaki K., Tao B., Heyrman R. et al. Assessment of Efficacy an Olmesartan in Pediatric Hypertension Study Group. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010; 55(6): 1323–1330. DOI:10.1161/HYPERTENSIONAHA.109.147702; Simonett G.D., von Vigier R.O., Konrad M., Rizzi M., Fossali E., Bianchetti M.G. Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. Pediatr Nephrol 2006; 21(10): 1480–1482.; Trachtman H., Frank R., Mahan J.D., Portman R., Restaino I., Matoo T.K. et al. Clinical trial of extended release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18: 548–553. DOI:10.1007/s00467-003-1134-0; Sica D.A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011; 13: 639–643. DOI:10.1111/j.1751-7176.2011.00512; Karnes J.H., Cooper-DeHoff R.M. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther 2009; 7: 689–702. DOI:10.1586/erc.09.31; Li J.S., Flynn J.T., Portman R., Davis I., Ogawa M., Shi H. et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study. J Pediatr 2010; 157(2): 282–287. DOI:10.1016/j.jpeds.2010.02.042; Meyers R.S., Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther 2011; 33: 1331–1356. DOI:10.1016/j.clinthera.2011.09.003; Poirier L., Lacourcière Y. The evolving role of β-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012; 28: 334–340. DOI:10.1016/j.cjca.2012.04.001; Batisky D.L., Sorof J.M., Sugg J., Llewellyn M., Klibaner M., Hainer J.W., et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 2007; 150(2): 134–139. DOI:10.1016/j.jpeds.2006.09.034; Sorof J.M., Cargo P., Graepel J., Humphrey D., King E., Rolf C. et al. β-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo controlled trial. Pediatr Nephrol 2002; 17(5): 345–350. DOI:10.1007/s00467-002-0851-0; Poirier L., Tobe S.W. Contemporary use of beta-blocker: clinical relevance of subclassification. Can J Cardiol 2014; 30: S9–15. DOI:10.1016/j.cjca.2013.12.001; Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–2219. DOI:10.1093/eurheartj/eht151; Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635–1642. DOI:10.1161/CIRCULATIONAHA.111.068064; Narayan H., Webb D.J. New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension. Curr Hypertens Rep 2016; 18(5): 34. DOI:10.1007/s11906-016-0643-8; Williams B., MacDonald T.M., Morant S., Webb D., Sever P., McInnes G. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment or drugresistant hypertension(PATHWAY-2): a randomised, doubleblind, crossover trial. Lancet 2015; 386(10008): 2059–2068. DOI:10.1016/S0140-6736(15)00257-3; White W.B., Turner J.R., Sica D.A. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., 2013. J Am Soc Hypertens 2014; 8(10): 743–757. DOI:10.1016/j.jash.2014.06.005; Redwine K., Howard L., Simpson P., Li S.H., Yan K., James L. et al. Effect of placebo on ambulatory blood pressure monitoring in children. Pediatr Nephrol 2012; 27(10): 1937–1942. DOI:10.1007/s00467-012-2191-z; Juhola J., Magnussen C.G., Berenson G.S., Venn A., Burns T.L., Sabin M.A. et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation 2013; 128: 217–224. DOI:10.1161/CIRCULATIONAHA.113.001614; Urbina E.M., Williams R.V., Alpert B.S., Collins R.T., Daniels S.R., Hayman L. et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54(5): 919–950. DOI:10.1161/HYPERTENSIONAHA.109.192639; Martino F., Puddu P.E., Pannarale G., Colantoni C., Martino E., Zanoni C. et al. Hypertension in children and adolescents attending a lipid clinic. Eur J Pediatr 2013; 172(12): 1573–1579. DOI:10.1007/s00431-013-2082-8

  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20